# EQUITY RESEARCH - COMPANY REPORT

# CHULARAT HOSPITAL

**CHG TB** 

# Growth stock at value price

- 2022E organic profit (excluding Covid revenue) to exceed pre-Covid by 74%; trading at a 40% discount to historical value.
- Strong 4Q21E organic profit (SSO and cash patients) and 6-7% dividend yield could catch the market's attention again.
- Maintain BUY with 2022 DCF-based TP of THB4.7.

# 2022E earnings to exceed pre-Covid by 128%

The market has overlooked CHG and its share price has fallen from its peak by 30% over the past seven months, mainly due to the argument that its "earnings have passed their peak in 3Q21 and Covid-related revenue will fade away". We believe this has already been priced in. We suggest investors look at CHG's organic core profit (excl. Covid-related), which we estimate to grow by 20% CAGR from THB0.7b in 2019 to THB1.3b in 2022. This means that 2022E organic core profit would exceed the pre-Covid level by 74%, while the stock is trading at a 40% discount at 21x 2022E P/E vs its 5-yr average of 35x; unjustified in our view. Including Covid-related contributions, CHG's 2022E core profit would be THB1.6b, exceeding the pre-Covid level by 128%.

# Expect 4Q21 profit to beat market expectation from organic profit

We expect a 4Q21 core profit of THB1.2b (above BBG's consensus estimate of THB0.9b). Although core profit may decline from THB1.6b in 3Q21 due to lower Covid-related revenue, we expect to see its organic operations recover to normal and possibly exceed the pre-Covid level. SSO revenue should jump by 40-50% y-y, led by additional revenue from chronic disease treatments during 2020, as the actual amount received was larger than the accrued amount. Non-Covid patients should also grow by 10% q-q, led by pent-up demand. We believe the market will focus on CHG's strong organic earnings post 4Q21 results.

# Offering a dividend yield of up to 6-7% for 2021

Normally, CHG pays a dividend of THB0.05/shr per year, implying only a 1-2% dividend yield. With strong 2021E earnings, we expect CHG to pay a dividend of up to THB0.20-0.23/shr (already paid interim THB0.02/shr) based on a 60-70% payout ratio (vs avg of 76% over past 3 years). This implies a dividend yield of 6-7%, and could grab the market's attention.

# Highest ROE, but trading at discount to peers and historical value

We revise up our 2021-22E core profit by 16-21% to reflect the strong organic earnings outlook and higher Covid-related revenue following the Omicron variant. CHG has the highest ROE at 24% vs its peers' average of 14%, while trading at an attractive 21x 2022E P/E (27x non-Covid profit) vs its peers' average of 34x and its 5-yr average of 35x.




Teerapol Udomvej, CFA teerapol.udo@fssia.com +66 2611 3535

	UNCHANGED
TARGET PRICE	THB4.70
CLOSE	THB3.12
UP/DOWNSIDE	+50.6%
PRIOR TP	THB4.70
CHANGE IN TP	UNCHANGED

TP vs CONSENSUS +10.3%

# **KEY STOCK DATA**

YE Dec (THB m)	2020	2021E	2022E	2023E
Revenue	5,433	11,342	7,872	7,085
Net profit	877	3,631	1,639	1,456
EPS (THB)	0.08	0.33	0.15	0.13
vs Consensus (%)	-	17.9	24.0	7.4
EBITDA	1,457	5,001	2,472	2,269
Core net profit	877	3,631	1,639	1,456
Core EPS (THB)	0.08	0.33	0.15	0.13
Chg. In EPS est. (%)	-	21.0	16.3	1.6
EPS growth (%)	21.9	314.3	(54.9)	(11.1)
Core P/E (x)	39.2	9.5	20.9	23.6
Dividend yield (%)	1.6	6.3	2.9	2.5
EV/EBITDA (x)	24.1	6.5	13.3	14.3
Price/book (x)	8.5	4.8	5.2	4.9
Net debt/Equity (%)	15.1	(29.2)	(24.8)	(29.2)
ROE (%)	22.7	65.3	24.0	21.4



Sources: Bloomberg consensus; FSSIA estimates

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT



# Investment thesis

CHG opened two new hospitals (RPC and 304 Inter) in 2H18 and they contributed an accumulated loss of THB70m in 2020 (8% of 2020 core profit). Both hospitals have already turned around, and we estimate that this should lead to an EBITDA margin improvement from 24% in 2019 to 32% in 2023.

CHG's revenue contributions from cash patients have gradually increased. This is another key factor to expand its EBITDA margin, in our view, as cash patients have a higher margin than Social Security Office (SSO) patients.

CHG should report strong earnings growth in 2022, led by the recovery of non-Covid cash patients coupled with Covid-related services, which should become recurring income going forward.

# **Company profile**

CHG operates a healthcare business covering the eastern part of Bangkok and its nearby provinces. The Group owns nine hospitals and four clinics.

www.chularat.com


# Principal activities (revenue, 2020)

- Cash patient revenue 59.1 %
- SSO patient revenue 33.3 %
- NHSO patient revenue 7.6 %

Source: Chularat Hospital

# Major shareholders

- Kannikar Plussind 18.1 %
- Apirum Panyapol 10.3 %
- Kobkul Panyapol 8.1 %
- Others 63.5 %



Source: Chularat Hospital

# Catalysts

Key potential growth drivers include 1) more SSO registered members; 2) rising demand for medical tourists; and 3) an improving EBITDA margin led by new hospitals.

# Risks to our call

Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.

# Event calendar

Event Date Feb 2022 4Q21 results announcement

# Key assumptions

	2021E	2022E	2023E
	(%)	(%)	(%)
SSO volume growth	1	4	3
SSO revenue / patient growth	1	1	4
OPD volume growth	20	(5)	6
OPD revenue / patient growth	13	(5)	5
IPD volume growth	(12)	23	9
IPD revenue / patient growth	35	(25)	5

Source: FSSIA estimates

#### Earnings sensitivity

- For every 1% increase in patient volume, we project 2023 earnings to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2023 earnings to rise by 3%, and vice versa, all else being equal.

Source: FSSIA estimates




# Organic core profit could exceed pre-Covid by 74% in 2022


Since the market is concerned about the decline of Covid-related revenue, we are focusing on organic core profit (excluding Covid-related services). We estimate that organic core profit would amount to THB1.1b in 2021. Based on our forecast, it should continue to grow by 17% to THB1.3b in 2022, driven by the recovery of both Thai and international non-Covid patients, a larger SSO registered member base and three new managed heart centres. 2022E organic core profit of THB1.3b should exceed the pre-Covid level by 74%.

However, Covid-related revenue should still remain in 2022 and will likely become recurring income going forward. We estimate Covid-related revenue of THB1.9b in 2022, accounting for 33% of 2021E Covid-related revenue of THB5.7b.






# Exhibit 2: Core profit including Covid-related



Sources: CHG; FSSIA estimates



# Exhibit 3: 2022E core profit breakdown


Source: FSSIA estimates

# Exhibit 4: 2022E key earnings growth items


Key growth items	Assumptions
SSO	Expect SSO registered members to increase by 30k
International patients	Expect international patient revenue, which normally contributes around 4-5% of total revenue (cTHB200m), to recover with an NPM of 20-25%
Non-Covid Thai patients	Expect non-Thai patient revenue in 2022 to grow by 6% with an NPM of 20%
Heart Centre management contract	Expect three new managed heart centres to contribute revenue of cTHB400m with an NPM of 15%
Interest savings	Expect CHG to gradually repay its debt thanks to its strong cashflow in 2021, and should reduce interest expenses by 50-60% in 2022
Covid-related services	Expect Covid-related revenue of THB1.9b in 2022, accounting for 33% of Covid-related revenue that we expect in 2021 with an NPM of 25%

Source: FSSIA estimates

# Exhibit 5: Non-Covid cash patient revenue



#### Exhibit 6: SSO revenue



Sources: CHG; FSSIA estimates

Sources: CHG; FSSIA estimates

# **4Q21E results preview**

We expect Covid-related revenue to decline by 42% q-q in 4Q21. Covid testing should drop from c1,000 cases per day in 3Q21 to c500 in 4Q21, while Covid patients should drop from c6,500 beds per day in 3Q21 to c3,500 beds per day in 4Q21 (3,000 beds in hospitels and 500 beds in hospitals/field hospitals). CHG should start to book Moderna vaccinations with an estimated of 90k doses in 4Q21. Overall, we estimate that Covid-related revenue contributions should drop from 69% of total revenue in 3Q21 to 50% in 4Q21.

Non-Covid patients should grow significantly by 10% q-q in 4Q21, led by pent-up demand as CHG allocated most of its capacity to serve Covid patients in 3Q21, while the capacity was reverted back to serve non-Covid patients in 4Q21.

We expect SSO revenue to jump by 47% q-q in 4Q21, driven by higher intensity treatments and additional revenue from chronic disease treatments during 2020, given that the actual amount received was larger than the accrued amount.

Overall, we estimate core profit to drop by 21% q-q to THB1.2b in 4Q21 from THB1.6b in 3Q21. However, it should jump almost 5x y-y.


# Exhibit 7: 4Q21E results preview

Year to Dec	4Q20	1Q21	2Q21	3Q21	4Q21E	E Change		2021E
	(THB m)	(q-q %)	- (y-y %)	(THB m)				
Revenue	1,511	1,415	2,071	4,390	3,461	(21)	129	11,342
Cost of sales (Incl. depreciation)	(1,000)	(995)	(1,206)	(2,159)	(1,661)	(23)	66	(5,971)
Gross profit	510	420	865	2,232	1,800	(19)	253	5,371
SG&A	(207)	(160)	(206)	(338)	(300)	(11)	45	(1,008)
Operating profit	303	260	659	1,893	1,500	(21)	395	4,362
Other operating income	13	57	64	67	67	0	402	260
Interest income	1	0	1	0	1	1,011	48	3
EBIT	317	318	724	1,961	1,568	(20)	394	4,626
Interest expense	(7)	(6)	(5)	(5)	(5)	0	(32)	(32)
EBT	310	312	718	1,956	1,563	(20)	404	4,593
Income tax	(57)	(63)	(143)	(377)	(313)	(17)	446	(938)
Minority interests	0.9	2.3	0.8	(15)	(12)	(22)	(1,378)	(24)
Core profit	254	252	576	1,564	1,239	(21)	388	3,631
Net income	254	252	576	1,564	1,239	(21)	388	3,631
Core EPS (THB)	0.02	0.02	0.05	0.14	0.11	(21)	388	0.33
No of shares (m)	11,000	11,000	11,000	11,000	11,000	0	0	11,000
Cost (excl. depreciation)	(912)	(908)	(1,121)	(2,071)	(1,571)	(24)	72	(5,593)
Depreciation & amoritisation	(88)	(87)	(86)	(87)	(90)	3	2	(378)
EBITDA	405	404	809	2,048	1,657	(19)	310	5,001
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)
Gross margin	34	30	42	51	52	1	18	47
SG&A/Revenue	14	11	10	8	9	1	(5)	9
EBITDA margin	27	29	39	47	48	1	21	44
Net profit margin	17	18	28	36	36	0	19	32
Operating stats	(y-y %)	(y-y %)	(y-y %)	(y-y %)	(у-у %)			
SSO revenue	22	6	2	(29)	na			
SSO registered members ('000)	440	448	457	460	na			
SSO revenue per head	22	5	(0)	(32)	na			
Cash-OPD revenue	18	15	86	29	na			
Cash-OPD visit number	6	(3)	51	11	na			
Cash-OPD revenue per head	11	18	23	16	na			
Cash-IPD revenue	(0)	(10)	40	35	na			
Cash-IPD admission number	(1)	(12)	9	(25)	na			
Cash-IPD revenue per head	0	3	29	80	na			

Sources: CHG; FSSIA estimates


#### Exhibit 8: Covid-related revenue

# (THB m)




Sources: CHG; FSSIA estimates

### Exhibit 10: Covid screening cases




# Exhibit 9: Core profit quarterly forecast



Sources: CHG; FSSIA estimates

# Exhibit 11: Covid patients in hospitels and hospital IPD



Sources: CHG; FSSIA estimates


# **Forecast and TP revisions**

We revise up our 2021-23E core profit by 2-21% to reflect the stronger outlook from organic growth and the potential benefit from higher Covid-related revenue following the Omicron variant. We maintain our 2022 DCF-based TP of THB4.7/shr, implying 32x 2022E P/E (vs 5-yr average of 35x).


# Highest ROE compared to peers, but trading undervalued

Using a PE/ROE matrix, we can see that CHG is in the undervalued area as it has the highest 2022E ROE of 24%, higher than its peers' average of 14%, while it trades at 21x 2022E P/E, lower than its peers' average of 34x.

# Exhibit 12: 2022E ROE comparison



# Exhibit 13: 2022E P/E and ROE matrix



Source: FSSIA estimates

#### Source: FSSIA estimates

# **Exhibit 14: Forecast revisions**

	Current				Previous		Change		
	2021E	2022E	2023E	2021E	2022E	2023E	2021E	2022E	2023E
	(THB m)	(THB m)	(%)	(%)	(%)				
SSO registered members ('000)	447	465	479	447	465	470	0.0	0.0	2.0
SSO revenue per head (THB)	4,130	4,171	4,338	4,007	4,087	4,251	3.1	2.1	2.1
Cash-OPD visits per day (no.)	3,093	2,939	3,115	3,093	2,939	3,115	0.0	0.0	0.0
Cash-OPD revenue per head (THB)	2,028	1,926	2,023	2,028	1,926	2,023	0.0	0.0	0.0
Cash-IPD admissions per day (no.)	162	199	217	162	199	217	0.0	0.0	0.0
Cash-IPD revenue per head (THB)	30,625	22,969	24,117	30,625	22,969	24,117	0.0	0.0	0.0
Revenue	11,342	7,872	7,085	10,187	6,433	6,843	11.3	22.4	3.5
EBITDA margin (%)	44.1	31.4	32.0	41.1	33.9	32.7	3.0	(2.5)	(0.7)
Core profit	3,631	1,639	1,456	3,002	1,410	1,433	21.0	16.3	1.6

Note: Change of items in percentage terms is represented in ppt change Source: FSSIA estimates

# Exhibit 15: DCF valuation

Cost of equity assumptions	(%)	Cost of debt assumptions	(%)
Risk-free rate	3.0	Pre-tax cost of debt	3.5
Market risk premium	8.0	Marginal tax rate	20.0
Stock beta	0.9		
Cost of equity, Ke	10.0	Net cost of debt, Kd	2.8
Weight applied	75.0	Weight applied	40.0
WACC	8.2		


DCF valuation estimate	(THB b)	(THB/share)	Comments
NPV	16.2	1.5	WACC 8.2%, risk-free rate 3%, risk premium 8%
Terminal value	34.1	3.1	Terminal growth 3%
Cash & liquid assets	1.8	0.2	At end-2022E
Investments	0.0	0.0	At end-2022E
Debt	(0.1)	(0.0)	At end-2022E
Minorities	(0.2)	(0.0)	At end-2022E
Residual ordinary equity	51.8	4.7	

#### Source: FSSIA estimates

# Exhibit 16: Historical P/E band



# Exhibit 17: Historical P/BV band



Sources: Bloomberg; FSSIA estimates

# Exhibit 18: Peer comparisons as of 10 Feb 2022

Company BBG Rec Share price ----Market ---- ROE -------- PBV ----- EV/ EBITDA ------ PE Target Upside Сар 21E 22E 21E 22E 21E 22E 21E 22E Current (LCY) (LCY) (%) (USD m) (%) (%) (x) (x) (x) (X) (X) (X) Thailand Bangkok Dusit Med Service BDMS TB BUY 23.10 29.00 25.5 11,248 53.1 36.4 8.1 11.6 4.4 4.1 23.1 18.3 BH TB BUY 152 50 170.00 127 0 514 65 50.8 Bumrungrad Hospital 11 5 3.713 54 132 71 27.6 BCH TB BUY 28.50 1,398 21.1 Bangkok Chain Hospital 18.30 55.7 7.9 61.0 18.6 3.8 4.1 5.3 11.7 Chularat Hospital CHG TB BUY 3.12 4.70 50.6 1,052 9.5 20.9 65.3 24.0 4.8 5.2 6.5 13.3 Praram 9 Hospital PR9 TB BUY 11.00 15.00 36.4 265 37.4 23.3 5.5 8.5 2.0 1.9 13.9 10.5 Thonburi Healthcare Group THG TB HOLD 42.00 32.50 (22.6) 1,091 38.5 78.5 11.3 5.4 4.2 4.3 21.2 29.5 Vibhavadi Medical Center VIBHA TB BUY 2.40 3.20 33.3 998 23.3 34.8 17.7 9.4 3.5 2.8 23.8 26.0 RAM TB BUY 35.25 48.00 36.2 1,296 23.1 21.3 13.5 3.1 10.1 Ramkhamhaeng Hospital 15.1 3.1 16.0 Rajthanee Hospital RJH TB n/a 32.50 n/a n/a 297 9.9 20.8 56.4 24.7 6.5 5.1 7.3 13.9 Ekachai Medical Care EKH TB n/a 7.40 n/a n/a 135 13.6 24.4 33.5 15.7 5.1 44 8.9 14.1 4.1 Thailand average 21,494 33.5 33.5 28.5 14.4 4.5 17.1 18.1 Regional RHC AU 64.57 10.586 31.4 36.1 3.6 3.6 12.3 Ramsay Health Care 11.3 9.7 12.4 n/a n/a n/a IHH SP 13,677 38.0 35.5 2.5 16.8 Ihh Healthcare Bhd 2.09 6.5 6.5 2.4 15.9 n/a n/a n/a 9.88 3,293 21.2 21.9 7.5 2.1 26.9 22.7 Ryman Healthcare RYM NZ n/a n/a n/a 12.2 1.9 Apollo Hospitals Enterprise APHS IN n/a 4,591 n/a n/a 8,771 768.8 69.4 2.4 18.4 18.2 15.7 60.5 30.1 Kpj Healthcare Berhad KPJ MK n/a 1.12 n/a n/a 1,161 86.2 28.7 2.8 7.4 2.5 2.2 16.6 12.7 Raffles Medical Group RFMD SP n/a 1.26 n/a n/a 1,751 30.7 30.7 8.4 8.6 2.7 2.5 17.1 16.1 Mitra Keluarga Karyasehat MIKA IJ n/a 2,260 n/a n/a 2,242 28.3 31.7 21.1 18.2 6.6 5.9 18.0 19.7 Aier Eye Hospital Group 300015 CH n/a 33.59 n/a n/a 28,557 77.2 57.9 20.1 22.0 21.3 14.6 44.4 35.2 **Regional average** 70,037 135.2 39.0 10.6 12.3 7.4 6.1 26.6 20.6 **Overall average** 91,532 78.7 35.9 20.6 5.8 5.0 21.3 19.2 13.5

Sources: Bloomberg; FSSIA estimates



# **Financial Statements**

Chularat Hospital

Profit and Loss (THB m) Year Ending Dec	2019	2020	2021E	2022E	2023E
Revenue	5,166	5,433	11,342	7,872	7,085
Cost of goods sold	(3,300)	(3,331)	(5,593)	(4,685)	(4,252)
Gross profit	1,866	2,102	5,749	3,187	2,833
Other operating income	22	29	260	300	300
Operating costs	(655)	(673)	(1,008)	(1,015)	(864)
Operating EBITDA	1,233	1,457	5,001	2,472	2,269
Depreciation	(330)	(354)	(378)	(401)	(428)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	903	1,104	4,622	2,072	1,841
Net financing costs	(37)	(33)	(29)	6	8
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	(14)	0	0	0	0
Profit before tax	852	1,071	4,593	2,077	1,849
Tax	(187)	(219)	(938)	(424)	(378)
Profit after tax	665	852	3,655	1,653	1,472
Minority interests	41	24	(24)	(14)	(15)
Preferred dividends	-	-	-	-	
Other items	-	-	-	-	-
Reported net profit	705	877	3,631	1,639	1,456
Non-recurring items & goodwill (net)	14	0	0	0	0
Recurring net profit	719	877	3,631	1,639	1,456
Per share (THB)					
Recurring EPS *	0.07	0.08	0.33	0.15	0.13
Reported EPS	0.06	0.08	0.33	0.15	0.13
DPS	0.05	0.05	0.20	0.09	0.08
Diluted shares (used to calculate per share data)	11,000	11,000	11,000	11,000	11,000
Growth					
Revenue (%)	17.2	5.2	108.8	(30.6)	(10.0)
Operating EBITDA (%)	16.2	18.2	243.1	(50.6)	(8.2)
Operating EBIT (%)	15.0	22.3	318.7	(55.2)	(11.1)
Recurring EPS (%)	13.4	21.9	314.3	(54.9)	(11.1)
Reported EPS (%)	11.3	24.3	314.3	(54.9)	(11.1)
Operating performance					
Gross margin inc. depreciation (%)	29.7	32.2	47.4	35.4	33.9
Gross margin of key business (%)	29.7	32.2	47.4	35.4	33.9
Operating EBITDA margin (%)	23.9	26.8	44.1	31.4	32.0
Operating EBIT margin (%)	17.5	20.3	40.8	26.3	26.0
Net margin (%)	13.9	16.1	32.0	20.8	20.6
Effective tax rate (%)	21.6	20.4	20.4	20.4	20.4
Dividend payout on recurring profit (%)	76.5	62.7	60.0	60.0	60.0
Interest cover (X)	24.2	33.6	159.5	(351.4)	(227.5)
Inventory days	16.7	18.6	15.7	21.5	20.6
Debtor days	27.6	31.1	17.3	29.4	36.5
Creditor days	64.9	64.5	49.8	68.5	65.6
Operating ROIC (%)	15.6	18.3	74.4	32.5	29.1
ROIC (%)	14.7	17.5	72.0	31.5	28.1
ROE (%)	19.8	22.7	65.3	24.0	21.4
ROA (%)	11.8	14.1	46.7	18.8	18.0
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2019	2020	2021E	2022E	2023E
Cash patient revenue	3,235	3,208	4,095	3,732	4,206
SSO patient revenue	1,578	1,811	1,847	1,940	2,079
NHSO patient revenue	353	413	5,400	2,200	800

Sources: Chularat Hospital; FSSIA estimates

# **Financial Statements**

Chularat Hospital

Cash Flow (THB m) Year Ending Dec	2019	2020	2021E	2022E	2023E
Recurring net profit	719	877	3,631	1,639	1,456
Depreciation	330	354	378	401	428
ssociates & minorities	-	-	-	-	
Other non-cash items	(31)	90	24	14	15
change in working capital	(123)	70	(305)	83	(61
ash flow from operations	895	1,390	3,729	2,137	1,839
Capex - maintenance	(713)	(400)	(400)	(400)	(400
Capex - new investment	-	-	-	-	
let acquisitions & disposals	0	0	0	0	(
Other investments (net)	-	-	-	-	(
Cash flow from investing	(713)	(400)	(400)	(400)	(400
Dividends paid	(550)	(550)	(550)	(2,179)	(984
quity finance	0	0	0	0	(
bebt finance	312 53	(360)	(270)	(809)	( (45
other financing cash flows		0	(24)	(14)	(15
ash flow from financing	(185)	(910)	(844)	(3,001)	(999
lon-recurring cash flows	-	-	-	-	
Other adjustments	0 0	0 <b>0</b>	0 <b>0</b>	0 <b>0</b>	(
let other adjustments					
lovement in cash	(3)	80	2,485	(1,264)	44(
ree cash flow to firm (FCFF)	222.33	1,026.10 629.99	3,361.15	1,749.10	1,441.29
ree cash flow to equity (FCFE)	546.91	629.99	3,034.92	914.37	1,423.77
er share (THB)	0.02	0.00	0.24	0.46	0.44
CFF per share	0.02 0.05	0.09 0.06	0.31 0.28	0.16 0.08	0.13
CFE per share Recurring cash flow per share	0.05	0.06	0.28	0.08	0.13 0.17
- · ·					
alance Sheet (THB m) Year Ending Dec	2019	2020	2021E	2022E	20238
angible fixed assets (gross)	6,237	6,581	6,981	7,381	7,78
ess: Accumulated depreciation	(2,017)	(2,308)	(2,686)	(3,087)	(3,515
angible fixed assets (net)	4,221	4,273	4,295	4,294	4,26
ntangible fixed assets (net)	47	47	47	47	4
ong-term financial assets	-	-	-	-	
vest. in associates & subsidiaries	0	0	0	0	(
Cash & equivalents	468	548	3,032	1,768	2,208
/C receivable	444	481	595	673	74
iventories	161	179	301	252	229
other current assets	692	555	1,159	805	724
urrent assets	1,764	1,763	5,087	3,498	3,90
Other assets	234	117	117	117	11
otal assets	6,266	6,201	9,547	7,956	8,336
Common equity	3,702	4,024	7,106	6,566	7,039
linorities etc.	193	169	169	169	169
otal shareholders' equity	3,895	4,193	7,275	6,735	7,208
ong term debt	573	609	609	0	
other long-term liabilities	115	124	124	124	124
ong-term liabilities	688	732	732	124	124
/C payable	607	570	957	802	728
hort term debt	966	570	300	100	10
ther current liabilities	109	135	283	196	17
urrent liabilities	1,682	1,275	1,540	1,098	1,004
otal liabilities and shareholders' equity	6,266	6,201	9,547	7,956	8,33
et working capital	580	510	815	732	793
ivested capital	5,082	4,948	5,274	5,191	5,223
Includes convertibles and preferred stock which is bein	g treated as debt				
er share (THB)					
ook value per share	0.34	0.37	0.65	0.60	0.6
angible book value per share	0.33	0.36	0.64	0.59	0.64
inancial strength					
et debt/equity (%)	27.5	15.1	(29.2)	(24.8)	(29.2
let debt/total assets (%)	17.1	10.2	(22.2)	(21.0)	(25.3
urrent ratio (x)	1.0	1.4	3.3	3.2	3.9
F interest cover (x)	15.7	20.2	105.7	(154.1)	(174.9
aluation	2019	2020	2021E	2022E	20231
ecurring P/E (x) *	47.7	39.2	9.5	20.9	23.
ecurring P/E @ target price (x) *	71.9	59.0	14.2	31.5	35.
leported P/E (x)	48.7	39.2	9.5	20.9	23.
ividend yield (%)	1.6	1.6	6.3	2.9	2.
rice/book (x)	9.3	8.5	4.8	5.2	4.9
rice/tangible book (x)	9.4	8.6	4.9	5.3	4.
V/EBITDA (x) **	28.9	24.1	6.5	13.3	14.
V/EBITDA @ target price (x) **	43.0	36.0	9.9	20.3	21.
V/invested capital (x)	7.0	7.1	6.1	6.3	6.2

Sources: Chularat Hospital; FSSIA estimates



# Corporate Governance report of Thai listed companies 2020

EXCELLE	INT LEVEL									
AAV	ADVANC	AF	AIRA	AKP	AKR	ALT	AMA	AMATA	AMATAV	ANAN
AOT	AP	ARIP	ARROW	ASP	BAFS	BANPU	BAY	BCP	BCPG	BDMS
BEC	BEM	BGRIM	BIZ	BKI	BLA	BOL	BPP	BRR	BTS	BWG
CENTEL	CFRESH	CHEWA	CHO	CIMBT	CK	CKP	CM	CNT	COL	COMAN
COTTO	CPALL	CPF	CPI	CPN	CSS	DELTA	DEMCO	DRT	DTAC	DTC
DV8	EA	EASTW	ECF	ECL	EGCO	EPG	ETE	FNS	FPI	FPT
FSMART	GBX	GC	GCAP	GEL	GFPT	GGC	GPSC	GRAMMY	GUNKUL	HANA
HARN	HMPRO	ICC	ICHI	Ш	ILINK	INTUCH	IRPC	IVL	JKN	JSP
JWD	к	KBANK	KCE	KKP	KSL	KTB	KTC	LANNA	LH	LHFG
LIT	LPN	MAKRO	MALEE	MBK	MBKET	MC	MCOT	METCO	MFEC	MINT
MONO	MOONG	MSC	MTC	NCH	NCL	NEP	NKI	NOBLE	NSI	NVD
NYT	OISHI	ORI	ОТО	PAP	PCSGH	PDJ	PG	PHOL	PLANB	PLANET
PLAT	PORT	PPS	PR9	PREB	PRG	PRM	PSH	PSL	PTG	PTT
PTTEP	PTTGC	PYLON	Q-CON	QH	QTC	RATCH	RS	S	S & J	SAAM
SABINA	SAMART	SAMTEL	SAT	SC	SCB	SCC	SCCC	SCG	SCN	SDC
SEAFCO	SEAOIL	SE-ED	SELIC	SENA	SIRI	SIS	SITHAI	SMK	SMPC	SNC
SONIC	SORKON	SPALI	SPI	SPRC	SPVI	SSSC	SST	STA	SUSCO	SUTHA
SVI	SYMC	SYNTEC	TACC	TASCO	TCAP	TFMAMA	THANA	THANI	THCOM	THG
THIP	THRE	THREL	TIP	TIPCO	TISCO	тк	TKT	TTB	TMILL	TNDT
TNL	TOA	TOP	TPBI	TQM	TRC	TSC	TSR	TSTE	TSTH	TTA
TTCL	TTW	TU	TVD	TVI	TVO	TWPC	U	UAC	UBIS	UV
VGI	VIH	WACOAL	WAVE	WHA	WHAUP	WICE	WINNER	TRUE		
VERY GO	OD LEVEL									
29		ACE	ACG		AEC	AEONTS	AGE	AH	AHC	

2S	ABM	ACE	ACG	ADB	AEC	AEONTS	AGE	AH	AHC	AIT
ALLA	AMANAH	AMARIN	APCO	APCS	APURE	AQUA	ASAP	ASEFA	ASIA	ASIAN
ASIMAR	ASK	ASN	ATP30	AUCT	AWC	AYUD	В	BA	BAM	BBL
BFIT	BGC	BJC	BJCHI	BROOK	BTW	CBG	CEN	CGH	CHARAN	CHAYO
CHG	CHOTI	CHOW	CI	CIG	CMC	COLOR	COM7	CPL	CRC	CRD
CSC	CSP	CWT	DCC	DCON	DDD	DOD	DOHOME	EASON	EE	ERW
ESTAR	FE	FLOYD	FN	FORTH	FSS	FTE	FVC	GENCO	GJS	GL
GLAND	GLOBAL	GLOCON	GPI	GULF	GYT	HPT	HTC	ICN	IFS	ILM
IMH	INET	INSURE	IRC	IRCP	IT	ITD	ITEL	J	JAS	JCK
JCKH	JMART	JMT	KBS	KCAR	KGI	KIAT	KOOL	KTIS	KWC	KWM
L&E	LALIN	LDC	LHK	LOXLEY	LPH	LRH	LST	Μ	MACO	MAJOR
MBAX	MEGA	META	MFC	MGT	MILL	MITSIB	MK	MODERN	MTI	MVP
NETBAY	NEX	NINE	NTV	NWR	OCC	OGC	OSP	PATO	PB	PDG
PDI	PICO	PIMO	PJW	PL	PM	PPP	PRIN	PRINC	PSTC	PT
QLT	RCL	RICHY	RML	RPC	RWI	S11	SALEE	SAMCO	SANKO	SAPPE
SAWAD	SCI	SCP	SE	SEG	SFP	SGF	SHR	SIAM	SINGER	SKE
SKR	SKY	SMIT	SMT	SNP	SPA	SPC	SPCG	SR	SRICHA	SSC
SSF	STANLY	STI	STPI	SUC	SUN	SYNEX	Т	TAE	TAKUNI	TBSP
TCC	TCMC	TEAM	TEAMG	TFG	TIGER	TITLE	TKN	TKS	TM	TMC
TMD	TMI	TMT	TNITY	TNP	TNR	TOG	TPA	TPAC	TPCORP	TPOLY
TPS	TRITN	TRT	TRU	TSE	TVT	TWP	UEC	UMI	UOBKH	UP
UPF	UPOIC	UT	UTP	UWC	VL	VNT	VPO	WIIK	WP	XO
YUASA	ZEN	ZIGA	ZMICO							

GOOD LEVEL												
7UP	А	ABICO	AJ	ALL	ALUCON	AMC	APP	ARIN	AS	AU		
B52	BC	BCH	BEAUTY	BGT	BH	BIG	BKD	BLAND	BM	BR		
BROCK	BSBM	BSM	BTNC	CAZ	CCP	CGD	CITY	CMAN	CMO	CMR		
CPT	CPW	CRANE	CSR	D	EKH	EP	ESSO	FMT	GIFT	GREEN		
GSC	GTB	HTECH	HUMAN	IHL	INOX	INSET	IP	JTS	JUBILE	KASET		
KCM	KKC	KUMWEL	KUN	KWG	KYE	LEE	MATCH	MATI	M-CHAI	MCS		
MDX	MJD	MM	MORE	NC	NDR	NER	NFC	NNCL	NPK	NUSA		
OCEAN	PAF	PF	PK	PLE	PMTA	POST	PPM	PRAKIT	PRECHA	PRIME		
PROUD	PTL	RBF	RCI	RJH	ROJNA	RP	RPH	RSP	SF	SFLEX		
SGP	SISB	SKN	SLP	SMART	SOLAR	SPG	SQ	SSP	STARK	STC		
SUPER	SVOA	TC	TCCC	THMUI	TIW	TNH	TOPP	TPCH	TPIPP	TPLAS		
TTI	TYCN	UKEM	UMS	VCOM	VRANDA	WIN	WORK	WPH				
		Description				Score Range						
Excellent							90-100					
Very Good							80-89					
Good							70-79					

#### Disclaimer:

The disclosure of the survey results of the Thai Institute of Directors Association ('IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey results may be changed after that date. FSS International Investment Advisory Company Limited does not confirm nor certify the accuracy of such survey results. \* CGR scoring should be considered with news regarding wrong doing of the company or director or executive of the company such unfair practice on securities trading, fraud,

and corruption SEC imposed a civil sanction against insider trading of director and executive; \*\* delisted

Source: Thai Institute of Directors Association (IOD); FSSIA's compilation

# **Anti-corruption Progress Indicator 2020**

CERTIFIED										
2S	ADVANC	AI	AIE	AIRA	AKP	AMA	AMANAH	AP	AQUA	ARROW
ASK	ASP	AYUD	В	BAFS	BANPU	BAY	BBL	BCH	BCP	BCPG
BGC	BGRIM	BJCHI	BKI	BLA	BPP	BROOK	BRR	BSBM	BTS	BWG
CEN	CENTEL	CFRESH	CGH	CHEWA	CHOTI	CHOW	CIG	CIMBT	СМ	CMC
COL	COM7	CPALL	CPF	CPI	CPN	CSC	DCC	DELTA	DEMCO	DIMET
DRT	DTAC	DTC	EASTW	ECL	EGCO	FE	FNS	FPI	FPT	FSS
FTE	GBX	GC	GCAP	GEL	GFPT	GGC	GJS	GPSC	GSTEEL	GUNKUL
HANA	HARN	HMPRO	HTC	ICC	ICHI	IFS	INET	INSURE	INTUCH	IRPC
ITEL	IVL	К	KASET	KBANK	KBS	KCAR	KCE	KGI	KKP	KSL
КТВ	KTC	KWC	L&E	LANNA	LHFG	LHK	LPN	LRH	Μ	MAKRO
MALEE	MBAX	MBK	MBKET	MC	MCOT	MFC	MFEC	MINT	MONO	MOONG
MPG	MSC	MTC	MTI	NBC	NEP	NINE	NKI	NMG	NNCL	NSI
NWR	OCC	OCEAN	OGC	ORI	PAP	PATO	PB	PCSGH	PDG	PDI
PDJ	PE	PG	PHOL	PL	PLANB	PLANET	PLAT	PM	PPP	PPPM
PPS	PREB	PRG	PRINC	PRM	PSH	PSL	PSTC	PT	PTG	PTT
PTTEP	PTTGC	PYLON	Q-CON	QH	QLT	QTC	RATCH	RML	RWI	S & J
SABINA	SAT	SC	SCB	SCC	SCCC	SCG	SCN	SEAOIL	SE-ED	SELIC
SENA	SGP	SIRI	SITHAI	SMIT	SMK	SMPC	SNC	SNP	SORKON	SPACK
SPC	SPI	SPRC	SRICHA	SSF	SSSC	SST	STA	SUSCO	SVI	SYNTEC
TAE	TAKUNI	TASCO	TBSP	TCAP	TCMC	TFG	TFI	TFMAMA	THANI	THCOM
THIP	THRE	THREL	TIP	TIPCO	TISCO	ТКТ	TTB	TMD	TMILL	TMT
TNITY	TNL	TNP	TNR	TOG	TOP	TPA	TPCORP	TPP	TRU	TSC
TSTH	TTCL	TU	TVD	TVI	TVO	TWPC	U	UBIS	UEC	UKEM
UOBKH	UWC	VGI	VIH	VNT	WACOAL	WHA	WHAUP	WICE	WIIK	XO
ZEN	TRUE									
DECLARED	)									
7UP	ABICO	AF	ALT	AMARIN	AMATA	AMATAV	ANAN	APURE	B52	BKD
BM	BROCK	BUI	СНО	CI	COTTO	DDD	EA	EFORL	EP	ERW
ESTAR	ETE	EVER	FSMART	GPI	ILINK	IRC	J	JKN	JMART	JMT
JSP	JTS	KWG	LDC	MAJOR	META	NCL	NOBLE	NOK	PK	PLE
ROJNA	SAAM	SAPPE	SCI	SE	SHANG	SINGER	SKR	SPALI	SSP	STANLY
SUPER	SYNEX	THAI	TKS	TOPP	TRITN	TTA	UPF	UV	WIN	ZIGA
Level										
Certified	This level in	This level indicates practical participation with thoroughly examination in relation to the recommended procedures from the audit committee or the SEC's								

This level indicates practical participation with thoroughly examination in relation to the recommended procedures from the audit committee or the SEC's certified auditor, being a certified member of Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) or already passed examination to ensure independence from external parties.

Declared This level indicates determination to participate in the Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC)

#### Disclaimer:

The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by Thaipat Institute, is made in order to comply with the policy and sustainable development plan for the listed companies of the Office of the Securities and Exchange Commission. Thaipat Institute made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of Thaipat Institute that is a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, FSS International Investment Advisory Company Limited does not confirm, verify, or certify the accuracy and completeness of the assessment results.

Note: Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of June 24, 2019) are categorised into: 1) companies that have declared their intention to join CAC, and; 2) companies certified by CAC.

Source: The Securities and Exchange Commission, Thailand; \* FSSIA's compilation

# **FINANSIA**

# GENERAL DISCLAIMER

# ANALYST(S) CERTIFICATION

#### Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSS makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSS has no intention to solicit investors to buy or sell any security in this report. In addition, FSS does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

Company	Ticker	Price	Rating	Valuation & Risks
Chularat Hospital	CHG TB	THB 3.12	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Bangkok Dusit Medical Services	BDMS TB	THB 23.10	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.
Bumrungrad Hospital	BH TB	THB 152.50	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.
Bangkok Chain Hospital	BCH TB	THB 18.30	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.
Praram 9 Hospital	PR9 TB	THB 11.00	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.
Thonburi Healthcare Group	THG TB	THB 42.00	HOLD	Downside risks to our DCF-based target price include 1) weak patient volume following the economic slowdown; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected expenses from new hospitals. Upside risk is big-lot sales of Jin Wellbeing County units.
Vibhavadi Medical Center	VIBHA TB	THB 2.40	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Ramkhamhaeng Hospital	RAM TB	THB 35.25	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) losses from its subsidiary companies.

Source: FSSIA estimates

#### Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited

FSSIA may incorporate the recommendations and target prices of companies currently covered by FSS Research into equity research reports, denoted by an 'FSS' before the recommendation. FSS Research is part of Finansia Syrus Securities Public Company Limited, which is the parent company of FSSIA.

All share prices are as at market close on 10-Feb-2022 unless otherwise stated.



# **RECOMMENDATION STRUCTURE**

### Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price\* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

#### **Industry Recommendations**

**Overweight.** The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

#### **Country (Strategy) Recommendations**

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

